Jingli Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jingli Liu has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Jinpin Li
Department of Neurology, The First Hospital of Guangxi Medical University, Nanning 530021, China
14 shared publicationsShenghua Li
Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, Nanning, China
10 shared publicationsJinggui Gao
Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, Nanning, China
9 shared publicationsQiaoling Song
9 shared publications- Xiaoxiao Sun
School of Energy Resources, China University of Geosciences, Beijing 100083, China
9 shared publications Zhenxiu Qin
Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, Nanning, China
9 shared publications
Latest Publications
- 5 November 2026
- Published by Bentham Science Publishers Ltd. in Current Neurovascular Research
- Vol. 24
Benzbromarone Attenuates Collagen-evoked Platelet Activation and Cerebral Ischemia-reperfusion Injury in a Rat Model
Background: Benzbromarone (BBR), a clinical drug for gout, has recently been identified as an inhibitor of Heat Shock Protein 47 (HSP47). HSP47 is known to participate in platelet- collagen interactions and thrombus formation. However, whether BBR exerts antiplatelet and neuroprotective effects in ischemic stroke remains unclear. Methods: Bleeding risk and cytotoxicity of BBR were assessed using tail bleeding time, coagulation parameters, LDH and CCK-8 assays, with aspirin and clopidogrel as comparators. The effects of BBR (1, 5, 10 μM) on collagen-induced platelet aggregation, adhesion, calcium mobilization and clot retraction were examined. The antithrombotic potential of BBR was evaluated in a FeCl3-induced carotid artery thrombosis model, and its neuroprotective potential in a Middle Cerebral Artery Occlusion (MCAO) model in rats. Phosphorylation levels of the Syk-PLCγ2-PKC and PI3K-Akt-GSK3β pathways were detected by western blotting. Results: In this study, BBR exhibited low bleeding risk and low cytotoxicity, similar to aspirin and clopidogrel. BBR dose-dependently reduced collagen-induced platelet aggregation, adhesion, [Ca2+] mobilization, and clot retraction. BBR delayed the Time to Occlusion (TTO) and inhibited arterial thrombosis. In MCAO rats, BBR also reduced infarct volume and ameliorated neurological deficits. Western blotting revealed that BBR decreased the phosphorylation levels of proteins in the Syk-PLCγ2-PKC and PI3K-Akt-GSK3β pathways. Discussion: As a known inhibitor of HSP47, BBR may suppress collagen-induced platelet activation and arterial thrombosis, possibly through modulating downstream signaling pathways of GPVI. Compared with conventional antiplatelet agents, BBR showed a favorable safety profile in rats, without significantly prolonging bleeding time or affecting liver and kidney function. These findings suggest that BBR represents a promising antiplatelet candidate with both efficacy and safety for ischemic stroke management. Conclusion: The present study demonstrates that BBR inhibits platelet activation and thrombosis, and attenuates cerebral ischemia-reperfusion injury in rats. Its protective effect may be associated with suppression of GPVI-related signaling pathways. BBR thus warrants further investigation as a potential candidate for acute-stage treatment of ischemic stroke.
- 5 November 2026
- Published by Bentham Science Publishers Ltd. in Current Neurovascular Research
- Vol. 24
Benzbromarone Attenuates Collagen-evoked Platelet Activation and Cerebral Ischemia-reperfusion Injury in a Rat Model
Background: Benzbromarone (BBR), a clinical drug for gout, has recently been identified as an inhibitor of Heat Shock Protein 47 (HSP47). HSP47 is known to participate in platelet- collagen interactions and thrombus formation. However, whether BBR exerts antiplatelet and neuroprotective effects in ischemic stroke remains unclear. Methods: Bleeding risk and cytotoxicity of BBR were assessed using tail bleeding time, coagulation parameters, LDH and CCK-8 assays, with aspirin and clopidogrel as comparators. The effects of BBR (1, 5, 10 μM) on collagen-induced platelet aggregation, adhesion, calcium mobilization and clot retraction were examined. The antithrombotic potential of BBR was evaluated in a FeCl3-induced carotid artery thrombosis model, and its neuroprotective potential in a Middle Cerebral Artery Occlusion (MCAO) model in rats. Phosphorylation levels of the Syk-PLCγ2-PKC and PI3K-Akt-GSK3β pathways were detected by western blotting. Results: In this study, BBR exhibited low bleeding risk and low cytotoxicity, similar to aspirin and clopidogrel. BBR dose-dependently reduced collagen-induced platelet aggregation, adhesion, [Ca2+] mobilization, and clot retraction. BBR delayed the Time to Occlusion (TTO) and inhibited arterial thrombosis. In MCAO rats, BBR also reduced infarct volume and ameliorated neurological deficits. Western blotting revealed that BBR decreased the phosphorylation levels of proteins in the Syk-PLCγ2-PKC and PI3K-Akt-GSK3β pathways. Discussion: As a known inhibitor of HSP47, BBR may suppress collagen-induced platelet activation and arterial thrombosis, possibly through modulating downstream signaling pathways of GPVI. Compared with conventional antiplatelet agents, BBR showed a favorable safety profile in rats, without significantly prolonging bleeding time or affecting liver and kidney function. These findings suggest that BBR represents a promising antiplatelet candidate with both efficacy and safety for ischemic stroke management. Conclusion: The present study demonstrates that BBR inhibits platelet activation and thrombosis, and attenuates cerebral ischemia-reperfusion injury in rats. Its protective effect may be associated with suppression of GPVI-related signaling pathways. BBR thus warrants further investigation as a potential candidate for acute-stage treatment of ischemic stroke.
- 22 May 2026
- Published by Elsevier in Molecular Immunology
- Vol. 195, 186-197
HSP47 inhibitor Col003 attenuates thromboinflammation after cerebral ischemia-reperfusion by suppressing GPVI-mediated CD84 shedding in platelets
- 22 May 2026
- Published by Elsevier in Molecular Immunology
- Vol. 195, 186-197
HSP47 inhibitor Col003 attenuates thromboinflammation after cerebral ischemia-reperfusion by suppressing GPVI-mediated CD84 shedding in platelets
- Open Access
- 23 January 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 236, 111745
HSP47 inhibitor Col003 inhibits glial scar formation and improves neurological function in ischemic stroke in rats
- 23 January 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 236, 111745
Open AccessHSP47 inhibitor Col003 inhibits glial scar formation and improves neurological function in ischemic stroke in rats
- 4 November 2025
- Published by Taylor & Francis in Neurological Research
- p. 1-12
HSP47 inhibitor Col003 may attenuates neurological impairment in chronic ischemic stroke rats by inhibiting LCN2
Ischemic stroke often causes severe neurological impairments. Our previous studies showed that Col003, a heat shock protein (HSP47) inhibitor, has neuroprotective effects in acute ischemic stroke, but its role in chronic ischemic stroke remains unclear. This study investigated gene changes in ischemic brain tissue of rats treated with Col003 after chronic ischemic stroke. Rats with middle cerebral artery occlusion (MCAO) received Col003 injections via tail vein daily for 14 days. Neurological function and cerebral infarct volume were measured post-ischemia. Rat brain tissues from Sham, Vehicle, and Col003 groups were analyzed by western blot (WB), real-time quantitative polymerase chain reaction (RT-qPCR), and RNA-Seq. Fourteen days post-MCAO, Col003 treatment significantly decreased cerebral infarct volume and enhanced neurological function scores in rats. There were 1956 genes up-regulated (Vehicle vs. Sham) and 251 genes down-regulated (Col003 vs. Vehicle) by RNA-Seq analysis, and 136 differentially expressed genes (DEGs) were identified by Venn diagram analysis. We screened genes closely associated with ischemic stroke, including lipocalin-2 (LCN2), from the top 20 significantly DEGs. Pathway enrichment analysis of DEGs showed that JAK-STAT pathway was strongly associated with chronic ischemic stroke. RT-qPCR and WB showed that LCN2 was upregulated in peri-infarct brain tissue at 14 days after ischemic stroke, and LCN2 was significantly reduced after Col003 treatment. Col003 decreased JAK2/STAT3 phosphorylation in ischemic brain tissue. In rats with chronic ischemic stroke, Col03 may lessen the size of the cerebral infarction and neurological impairments by blocking LCN2 through the JAK2/STAT3 signaling pathway.
- 4 November 2025
- Published by Taylor & Francis in Neurological Research
- p. 1-12
HSP47 inhibitor Col003 may attenuates neurological impairment in chronic ischemic stroke rats by inhibiting LCN2
Ischemic stroke often causes severe neurological impairments. Our previous studies showed that Col003, a heat shock protein (HSP47) inhibitor, has neuroprotective effects in acute ischemic stroke, but its role in chronic ischemic stroke remains unclear. This study investigated gene changes in ischemic brain tissue of rats treated with Col003 after chronic ischemic stroke. Rats with middle cerebral artery occlusion (MCAO) received Col003 injections via tail vein daily for 14 days. Neurological function and cerebral infarct volume were measured post-ischemia. Rat brain tissues from Sham, Vehicle, and Col003 groups were analyzed by western blot (WB), real-time quantitative polymerase chain reaction (RT-qPCR), and RNA-Seq. Fourteen days post-MCAO, Col003 treatment significantly decreased cerebral infarct volume and enhanced neurological function scores in rats. There were 1956 genes up-regulated (Vehicle vs. Sham) and 251 genes down-regulated (Col003 vs. Vehicle) by RNA-Seq analysis, and 136 differentially expressed genes (DEGs) were identified by Venn diagram analysis. We screened genes closely associated with ischemic stroke, including lipocalin-2 (LCN2), from the top 20 significantly DEGs. Pathway enrichment analysis of DEGs showed that JAK-STAT pathway was strongly associated with chronic ischemic stroke. RT-qPCR and WB showed that LCN2 was upregulated in peri-infarct brain tissue at 14 days after ischemic stroke, and LCN2 was significantly reduced after Col003 treatment. Col003 decreased JAK2/STAT3 phosphorylation in ischemic brain tissue. In rats with chronic ischemic stroke, Col03 may lessen the size of the cerebral infarction and neurological impairments by blocking LCN2 through the JAK2/STAT3 signaling pathway.
- 19 May 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 386, 119437
U-shaped association between systemic immune-inflammatory index and depression in U.S. adults with hypertension
- 19 May 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 386, 119437
U-shaped association between systemic immune-inflammatory index and depression in U.S. adults with hypertension
- 23 December 2024
- Published by Springer Nature in Histochemistry and Cell Biology
- Vol. 163 (1) , 1-10
Ku70 silencing aggravates oxygen–glucose deprivation/reperfusion-induced injury by activation of the p53 apoptotic pathway in rat cortical astrocytes
Oxidative stress-induced DNA damage is an important mechanism that leads to the death of neuronal cells after ischemic stroke. Our previous study found that Ku70 was highly expressed in ischemic brain tissue of rats after cerebral ischemia–reperfusion injury. However, the role of Ku70 in glucose–oxygen deprivation/reperfusion (OGD/R) in astrocytes has not been reported. Therefore, we investigated the effect and mechanism of Ku70 on OGD/R-induced astrocyte injury in rats. Rat astrocytes were cultured in vitro to establish the OGD/R-induced injury model and transfected with small interfering RNA (siRNA) to disturb Ku70 expression. Real-time quantitative polymerase chain reaction (RT-qPCR), western blotting, and immunofluorescence were performed to assay the expression of mRNA and proteins. Cell viability, apoptosis, and ROS accumulation were determined by CCK-8 assay, flow cytometry, and fluorescence microscopy, respectively. Our results showed Ku70 can be expressed in both the nucleus and cytoplasm of astrocytes, although mainly in the nucleus. Ku70 expression showed a trend of first increasing and then decreasing after OGD/R, reaching its highest change at 24 h of reoxygenation. OGD/R induced ROS production and DNA damage in rat astrocytes, and Ku70 silencing further increased ROS production and DNA lesions, which aggravated astrocyte injury and apoptosis. Furthermore, the expression of p53, Bax, and caspase 3 proteins significantly increased after OGD/R in astrocytes, and downregulation of Ku70 further enhanced expression of the above proteins. These results indicate that Ku70 silencing promotes OGD/R-induced astrocyte apoptosis, which may be associated with p53 apoptotic pathway activation. Our study suggests that Ku70 may be a novel target for cerebral ischemia–reperfusion injury therapy.
- 23 December 2024
- Published by Springer Nature in Histochemistry and Cell Biology
- Vol. 163 (1) , 1-10
Ku70 silencing aggravates oxygen–glucose deprivation/reperfusion-induced injury by activation of the p53 apoptotic pathway in rat cortical astrocytes
Oxidative stress-induced DNA damage is an important mechanism that leads to the death of neuronal cells after ischemic stroke. Our previous study found that Ku70 was highly expressed in ischemic brain tissue of rats after cerebral ischemia–reperfusion injury. However, the role of Ku70 in glucose–oxygen deprivation/reperfusion (OGD/R) in astrocytes has not been reported. Therefore, we investigated the effect and mechanism of Ku70 on OGD/R-induced astrocyte injury in rats. Rat astrocytes were cultured in vitro to establish the OGD/R-induced injury model and transfected with small interfering RNA (siRNA) to disturb Ku70 expression. Real-time quantitative polymerase chain reaction (RT-qPCR), western blotting, and immunofluorescence were performed to assay the expression of mRNA and proteins. Cell viability, apoptosis, and ROS accumulation were determined by CCK-8 assay, flow cytometry, and fluorescence microscopy, respectively. Our results showed Ku70 can be expressed in both the nucleus and cytoplasm of astrocytes, although mainly in the nucleus. Ku70 expression showed a trend of first increasing and then decreasing after OGD/R, reaching its highest change at 24 h of reoxygenation. OGD/R induced ROS production and DNA damage in rat astrocytes, and Ku70 silencing further increased ROS production and DNA lesions, which aggravated astrocyte injury and apoptosis. Furthermore, the expression of p53, Bax, and caspase 3 proteins significantly increased after OGD/R in astrocytes, and downregulation of Ku70 further enhanced expression of the above proteins. These results indicate that Ku70 silencing promotes OGD/R-induced astrocyte apoptosis, which may be associated with p53 apoptotic pathway activation. Our study suggests that Ku70 may be a novel target for cerebral ischemia–reperfusion injury therapy.
- Open Access
- 30 August 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (08) , 748-755
New role of astrocytes in neuroprotective mechanisms after ischemic stroke
Astrocytes are the most abundant cell subtypes in the central nervous system. Previous studies believed that astrocytes are supporting cells in the brain, which only provide nutrients for neurons. However, recent studies have found that astrocytes have more crucial and complex functions in the brain, such as neurogenesis, phagocytosis, and ischemic tolerance. After an ischemic stroke, the activated astrocytes can exert neuroprotective or neurotoxic effects through a variety of pathways. In this review, we will discuss the neuroprotective mechanisms of astrocytes in cerebral ischemia, and mainly focus on reactive astrocytosis or glial scar, neurogenesis, phagocytosis, and cerebral ischemic tolerance, for providing new strategies for the clinical treatment of stroke.
- 30 August 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (08) , 748-755
Open AccessNew role of astrocytes in neuroprotective mechanisms after ischemic stroke
Astrocytes are the most abundant cell subtypes in the central nervous system. Previous studies believed that astrocytes are supporting cells in the brain, which only provide nutrients for neurons. However, recent studies have found that astrocytes have more crucial and complex functions in the brain, such as neurogenesis, phagocytosis, and ischemic tolerance. After an ischemic stroke, the activated astrocytes can exert neuroprotective or neurotoxic effects through a variety of pathways. In this review, we will discuss the neuroprotective mechanisms of astrocytes in cerebral ischemia, and mainly focus on reactive astrocytosis or glial scar, neurogenesis, phagocytosis, and cerebral ischemic tolerance, for providing new strategies for the clinical treatment of stroke.
- Open Access
- 31 July 2023
- Published by Springer Nature in BMC Neuroscience
- Vol. 24 (1) , 1-15
Transcriptome analysis reveals the neuroprotective effect of Dlg4 against fastigial nucleus stimulation-induced ischemia/reperfusion injury in rats
Background: Previous studies have demonstrated that electrical stimulation of the cerebellar fastigial nucleus (FNS) can considerably decrease infarction volume and improve neurofunction restoration following cerebral ischemia. Nevertheless, the molecular mechanism of the neuroprotective effect of FNS is still vague. Methods: In this study, we developed a rat model of ischemia/reperfusion that included 1 h FNS followed by reperfusion for 3, 6, 12, 24, and 72 h. The expression profile of molecular alterations in brain tissues was obtained by transcriptome sequencing at five different time points. The function and pathway of miRNA expression pattern and core genes were annotated by Allen Brain Atlas, STRING database and Cytoscape software, so as to explore the mechanism of FNS-mediated neuroprotection. Results: The results indicated that FNS is associated with the neurotransmitter cycle pathway. FNS may regulate the release of monoamine neurotransmitters in synaptic vesicles by targeting the corresponding miRNAs through core Dlg4 gene, stimulate the Alternative polyadenylation (APA) incident’s anti -apoptosis effect on the brain, and stimulate the interaction activation of neurons in cerebellum, cortex/thalamus and other brain regions, regulate neurovascular coupling, and reduce cerebral damage. Conclusion: FNS may activate neuronal and neurovascular coupling by regulating the release of neurotransmitters in synaptic vesicles through the methylation of core Dlg4 gene and the corresponding transcription factors and protein kinases, inducing the anti-apoptotic mechanism of APA events. The findings from our investigation offer a new perspective on the way brain tissue responds to FNS-driven neuroprotection.
- 31 July 2023
- Published by Springer Nature in BMC Neuroscience
- Vol. 24 (1) , 1-15
Open AccessTranscriptome analysis reveals the neuroprotective effect of Dlg4 against fastigial nucleus stimulation-induced ischemia/reperfusion injury in rats
Background: Previous studies have demonstrated that electrical stimulation of the cerebellar fastigial nucleus (FNS) can considerably decrease infarction volume and improve neurofunction restoration following cerebral ischemia. Nevertheless, the molecular mechanism of the neuroprotective effect of FNS is still vague. Methods: In this study, we developed a rat model of ischemia/reperfusion that included 1 h FNS followed by reperfusion for 3, 6, 12, 24, and 72 h. The expression profile of molecular alterations in brain tissues was obtained by transcriptome sequencing at five different time points. The function and pathway of miRNA expression pattern and core genes were annotated by Allen Brain Atlas, STRING database and Cytoscape software, so as to explore the mechanism of FNS-mediated neuroprotection. Results: The results indicated that FNS is associated with the neurotransmitter cycle pathway. FNS may regulate the release of monoamine neurotransmitters in synaptic vesicles by targeting the corresponding miRNAs through core Dlg4 gene, stimulate the Alternative polyadenylation (APA) incident’s anti -apoptosis effect on the brain, and stimulate the interaction activation of neurons in cerebellum, cortex/thalamus and other brain regions, regulate neurovascular coupling, and reduce cerebral damage. Conclusion: FNS may activate neuronal and neurovascular coupling by regulating the release of neurotransmitters in synaptic vesicles through the methylation of core Dlg4 gene and the corresponding transcription factors and protein kinases, inducing the anti-apoptotic mechanism of APA events. The findings from our investigation offer a new perspective on the way brain tissue responds to FNS-driven neuroprotection.
- Open Access
- 14 April 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (4) , 659
Autoimmune Glial Fibrillary Acidic Protein (Gfap) Astrocytopa-Thy Accompanied with Reversible Splenial Lesion Syndrome (RESLES): A Case Report and Literature Review
Background: Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy usually presents as meningoencephalomyelitis. Many patients developed flu-like symptoms preceding the neurologic symptoms. Reversible lesion in the splenium of the corpus callosum (SCC) is a clinical and radiological syndrome secondary to many kinds of etiologies, including infections, which is termed RESLES. Case presentation: we reported a case developing irregularly high fever, both temporal pain, low limbs fatigue with frequent urination admitted to our neurology department. CSF test showed GFAP-IgG positive, elevated WBC counts and protein, with low glucose and chlorine, while MRI showed a reversible lesion on SCC, leading us to diagnose autoimmune GFAP autocytopathy accompanied with RESLES. The boy had significantly improved after anti-virus and steroids therapy. Discussion: Autoimmune GFAP autocytopathy accompanied with RESLES is rarely seen, and pathogenesis for the co-existence has not been clarified. Autoimmune GFAP autocytopathy and RESLES are both related to viral infection. Our case covered infectious symptoms and improved after antiviral treatment, suggesting virus infection may perform a key role in pathogenesis.
- 14 April 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (4) , 659
Open AccessAutoimmune Glial Fibrillary Acidic Protein (Gfap) Astrocytopa-Thy Accompanied with Reversible Splenial Lesion Syndrome (RESLES): A Case Report and Literature Review
Background: Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy usually presents as meningoencephalomyelitis. Many patients developed flu-like symptoms preceding the neurologic symptoms. Reversible lesion in the splenium of the corpus callosum (SCC) is a clinical and radiological syndrome secondary to many kinds of etiologies, including infections, which is termed RESLES. Case presentation: we reported a case developing irregularly high fever, both temporal pain, low limbs fatigue with frequent urination admitted to our neurology department. CSF test showed GFAP-IgG positive, elevated WBC counts and protein, with low glucose and chlorine, while MRI showed a reversible lesion on SCC, leading us to diagnose autoimmune GFAP autocytopathy accompanied with RESLES. The boy had significantly improved after anti-virus and steroids therapy. Discussion: Autoimmune GFAP autocytopathy accompanied with RESLES is rarely seen, and pathogenesis for the co-existence has not been clarified. Autoimmune GFAP autocytopathy and RESLES are both related to viral infection. Our case covered infectious symptoms and improved after antiviral treatment, suggesting virus infection may perform a key role in pathogenesis.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Quantitative summary of the inhibition of RTK phosphorylation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Quantitative summary of the inhibition of RTK phosphorylation.